NCT05512884 is a NA clinical trial of Speeded anomia therapy in Aphasia, sponsored by University of Cambridge.

Who is sponsoring NCT05512884?

NCT05512884 is sponsored by University of Cambridge.

What drugs are being tested in NCT05512884?

Interventions in NCT05512884: Speeded anomia therapy.

Is NCT05512884 still recruiting?

NCT05512884 is currently status unknown. Last updated 19 January 2023.

Last reviewed 2023-01-19 · How we verify

NCT05512884

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Speeded Anomia Treatment in Chronic Post-stroke Aphasia

Status unknown NA Last updated 19 January 2023

What this trial tests

NA trial testing Speeded anomia therapy in Aphasia in 100 participants. Status unknown.

Timeline

15 January 2023

Primary endpoint
1 September 2023

1 September 2023

Quick facts

Lead sponsor	University of Cambridge
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	15 January 2023
Primary completion	1 September 2023
Estimated completion	1 September 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Speeded anomia therapy

Conditions studied

Aphasia — all drugs for Aphasia →

Sponsor

University of Cambridge

Who can join

18 and older, any sex, with Aphasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of the study is to investigate the effect of a novel, speeded anomia therapy (Conroy et al., 2018) in a large population of patients with chronic post-stroke aphasia. The treatment will be delivered via a web application (QuickWord).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aphasia

Currently open trials in the same condition.

NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
NCT07397923 — Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia · Phase 2 · recruiting
NCT07281313 — Aphasia Physical EXercise Study: Randomized Trial · NA · recruiting
NCT06990997 — Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia · NA · recruiting
NCT06974279 — Post-Stroke Aphasia TMS · NA · recruiting

Other University of Cambridge trials

Trials by the same sponsor.

NCT07106216 — Evaluating Near-infrared Spectroscopy Devices for Monitoring Traumatic Brain Injury · not yet recruiting
NCT07341230 — Deep Brain Stimulation to Understand and Treat Addiction · NA · recruiting
NCT07154836 — Call for Life: Exploring mHealth Solutions for Enhancing Childhood Vaccinations Among Displaced Children in Conflict-aff · NA · enrolling by invitation
NCT06844539 — taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs · NA · recruiting
NCT07026656 — Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-assoc · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05512884 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cambridge
Last refreshed: 19 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05512884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing